193 related articles for article (PubMed ID: 35087132)
41. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
[TBL] [Abstract][Full Text] [Related]
42. Hypoxia and EGF Stimulation Regulate VEGF Expression in Human Glioblastoma Multiforme (GBM) Cells by Differential Regulation of the PI3K/Rho-GTPase and MAPK Pathways.
Nicolas S; Abdellatef S; Haddad MA; Fakhoury I; El-Sibai M
Cells; 2019 Nov; 8(11):. PubMed ID: 31698752
[TBL] [Abstract][Full Text] [Related]
43. IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.
Meng ZW; Zhang L; Cai XR; Wang X; She FF; Chen YL
Sci Rep; 2023 Oct; 13(1):18711. PubMed ID: 37907543
[TBL] [Abstract][Full Text] [Related]
44. Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness.
Chidambaram A; Fillmore HL; Van Meter TE; Dumur CI; Broaddus WC
J Neurosurg; 2012 Apr; 116(4):843-53. PubMed ID: 22313360
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.
Peng Y; He X; Chen H; Duan H; Shao B; Yang F; Li H; Yang P; Zeng Y; Zheng J; Li Y; Hu J; Lin L; Teng L
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061180
[TBL] [Abstract][Full Text] [Related]
46. Genetic manipulation of adhesion GPCR CD97/ADGRE5 modulates invasion in patient-derived glioma stem cells.
Eichberg DG; Slepak TI; Pascoini AL; Komotar RJ; Ivan ME
J Neurooncol; 2021 Jul; 153(3):383-391. PubMed ID: 34028660
[TBL] [Abstract][Full Text] [Related]
47. C-type lectin domain family 5, member A (CLEC5A, MDL-1) promotes brain glioblastoma tumorigenesis by regulating PI3K/Akt signalling.
Fan HW; Ni Q; Fan YN; Ma ZX; Li YB
Cell Prolif; 2019 May; 52(3):e12584. PubMed ID: 30834619
[TBL] [Abstract][Full Text] [Related]
48. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
[TBL] [Abstract][Full Text] [Related]
49. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
Vitucci M; Karpinich NO; Bash RE; Werneke AM; Schmid RS; White KK; McNeill RS; Huff B; Wang S; Van Dyke T; Miller CR
Neuro Oncol; 2013 Oct; 15(10):1317-29. PubMed ID: 23814263
[TBL] [Abstract][Full Text] [Related]
50. IL-17A promotes cell migration and invasion of glioblastoma cells via activation of PI3K/AKT signalling pathway.
Zheng Q; Diao S; Wang Q; Zhu C; Sun X; Yin B; Zhang X; Meng X; Wang B
J Cell Mol Med; 2019 Jan; 23(1):357-369. PubMed ID: 30353649
[TBL] [Abstract][Full Text] [Related]
51. Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma.
Chang L; Zhao D; Liu HB; Wang QS; Zhang P; Li CL; Du WZ; Wang HJ; Liu X; Zhang ZR; Jiang CL
Mol Med Rep; 2015 Nov; 12(5):6702-10. PubMed ID: 26299938
[TBL] [Abstract][Full Text] [Related]
52. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
53. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
[TBL] [Abstract][Full Text] [Related]
54. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
55. MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways.
Yao Y; Xue Y; Ma J; Shang C; Wang P; Liu L; Liu W; Li Z; Qu S; Li Z; Liu Y
PLoS One; 2014; 9(4):e95060. PubMed ID: 24736727
[TBL] [Abstract][Full Text] [Related]
56. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
57. Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines.
Dutra-Oliveira A; Monteiro RQ; Mariano-Oliveira A
Biochem Biophys Res Commun; 2012 May; 421(2):221-7. PubMed ID: 22497886
[TBL] [Abstract][Full Text] [Related]
58. SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
Xue Z; Wang J; Wang Z; Liu J; Zhao J; Liu X; Zhang Y; Liu G; Zhao Z; Li W; Zhang Q; Li X; Huang B; Wang X
BMC Cancer; 2023 Jun; 23(1):589. PubMed ID: 37365560
[TBL] [Abstract][Full Text] [Related]
59. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
[TBL] [Abstract][Full Text] [Related]
60. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
